The Latest Cardiac and Vascular News
ST. LOUIS, Aug. 08, 2019 (GLOBE NEWSWIRE) — Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2019. In a separate press release issued concurrently with this release, Stereotaxis announced a $25 million private […]
ST. LOUIS, June 18, 2019 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the first graduating class from its Robotic Electrophysiology Fellows Program. The Robotic Electrophysiology Fellows Program is designed to enhance the traditional electrophysiology fellowship […]
Innovative robotic surgery system, Stereotaxis Genesis™ RMN, enriches robotic magnetic navigation with increased efficiency, reduced size, and enhanced lab experience Genesis RMN System to be available in combination with Stereotaxis Imaging Model S, a next-generation x-ray system offered as part of a complete robotic electrophysiology lab solution Combined technologies greatly […]
Development of next generation robotically-navigated magnetic ablation catheter fully owned by Stereotaxis Catheter designed to enhance patient care, improve therapy delivery, simplify catheter navigation, and strengthen commitment to open ecosystem Entered into additional business agreements to support a long-term broad collaboration in electrophysiology ST. LOUIS and RHEINFELDEN, Germany, May 09, […]
ST. LOUIS, March 12, 2019 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was an extremely active year at Stereotaxis with progress […]
ST. LOUIS, Feb. 19, 2019 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to participate in the BTIG Healthcare Investor Conference in Snowbird, UT, on February […]
ST. LOUIS, Jan. 24, 2019 (GLOBE NEWSWIRE) — Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias announced today a partnership with Kansas City Heart Rhythm Institute to bring new and cutting-edge treatments to arrhythmia patients. Kansas City Heart Rhythm Institute (KCHRI), a […]
ST. LOUIS, Nov. 26, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to present at the 11th Annual LD Micro Main Event investor conference. Mr. Fischel […]
ST. LOUIS, Nov. 12, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2018. “We continue to make meaningful progress on our strategic innovation initiatives, and expect […]
ST. LOUIS, Nov. 02, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 third quarter ended September 30, 2018 on Monday, November 12, 2018 before the open […]
